| Literature DB >> 1537026 |
A Mukherjee1, R Persad, P J Smith.
Abstract
A total of 21 patients received intravesical BCG for the prevention of recurrence of superficial transitional cell carcinoma of the bladder. Twelve patients received the Glaxo strain and 9 the Pasteur strain of the bacillus. Although thought to have different anti-tumour activities owing to a difference in antigenicity, these 2 strains produced similar tumour-free rates at 5 years' mean follow-up with an overall tumour-free rate of 43%.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1537026 DOI： 10.1111/j.1464-410x.1992.tb15486.x
Source DB: PubMed Journal: Br J Urol ISSN： 0007-1331